Orthocell presents study data at key conferences

Company News

Orthocell has announced that positive, mean two year follow up data for its Ortho-ACITM treatment for articular cartilage defects of the knee and ankle will be presented at two leading regional orthopaedic association annual scientific meetings today.

According to the company, the retrospective analysis of 38 patients with symptomatic cartilage defects of the knee, showed 89 per cent good to excellent outcomes on MRI assessment and 83 per cent good to excellent outcomes on arthroscopic assessment.

The study was conducted by leading Melbourne orthopaedic surgeon Dr Raymond Crowe at Epworth Hospital in conjunction with the University of WA.

The first of the presentations will be at the Australian Orthopaedic Association’s (AOA) annual scientific meeting in Brisbane.

The data will also be presented at the Singaporean Orthopaedic Association’s annual scientific meeting starting today.

“The presentation of this clinical data and research data at these important regional orthopaedic meetings demonstrates the effectiveness of Ortho-ACITM in the regeneration of articular cartilage defects,” said Orthocell CEO, Mr Paul Anderson.

“These defects are often difficult to treat and can lead to degenerative osteoarthritis so a consistent and cost effective treatment is highly desired.

“As the population ages, mobility becomes a significant issue and so doctors and patients are seeking out proven treatments to increase patients’ mobility and quality of life,” he said.